Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 5
2005 3
2006 1
2007 4
2008 3
2009 2
2010 2
2011 2
2015 3
2016 1
2017 4
2018 9
2019 5
2020 10
2021 12
2022 8
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W. Ghia P, et al. Among authors: musuraca g. Hemasphere. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36398134 Free PMC article.
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. Ghia P, et al. Among authors: musuraca g. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27. J Clin Oncol. 2020. PMID: 32459600 Clinical Trial.
How I Manage Chronic Lymphocytic Leukemia.
Nasnas P, Cerchione C, Musuraca G, Martinelli G, Ferrajoli A. Nasnas P, et al. Among authors: musuraca g. Hematol Rep. 2023 Aug 1;15(3):454-464. doi: 10.3390/hematolrep15030047. Hematol Rep. 2023. PMID: 37606492 Free PMC article. Review.
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi.
Merli F, Luminari S, Tucci A, Arcari A, Rigacci L, Hawkes E, Chiattone CS, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Puccini B, Barraclough A, Delamain MT, Ferrero S, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli VR, Marino D, Balzarotti M, Cox MC, Zanni M, Di Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti E, Marcheselli L, Mammi C, Spina M. Merli F, et al. Among authors: musuraca g. J Clin Oncol. 2021 Apr 10;39(11):1214-1222. doi: 10.1200/JCO.20.02465. Epub 2021 Feb 12. J Clin Oncol. 2021. PMID: 33577377 Free article.
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
Gini G, Tani M, Tucci A, Marcheselli L, Cesaretti M, Bellei M, Pascarella A, Ballerini F, Petrini M, Merli F, Olivieri A, Lanza F, Annibali O, Zilioli VR, Liberati AM, Tisi MC, Arcari A, Marino D, Musuraca G, Pavone V, Fabbri A, Pozzi S, Mannina D, Plenteda C, Celli M, Luminari S. Gini G, et al. Among authors: musuraca g. Blood. 2023 Oct 26;142(17):1438-1447. doi: 10.1182/blood.2022019173. Blood. 2023. PMID: 37418685 Clinical Trial.
Hydroxychloroquine as Prophylaxis for COVID-19: A Review.
Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, Cerchione C, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O. Monti M, et al. Among authors: musuraca g. Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020. Front Pharmacol. 2020. PMID: 33343376 Free PMC article. Review.
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon.
Martino M, Naso V, Loteta B, Canale FA, Pugliese M, Alati C, Musuraca G, Nappi D, Gaimari A, Nicolini F, Mazza M, Bravaccini S, Derudas D, Martinelli G, Cerchione C. Martino M, et al. Among authors: musuraca g. Int J Mol Sci. 2022 Nov 1;23(21):13332. doi: 10.3390/ijms232113332. Int J Mol Sci. 2022. PMID: 36362130 Free PMC article. Review.
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.
Gottardi M, Simonetti G, Sperotto A, Nappi D, Ghelli Luserna di Rorà A, Padella A, Norata M, Giannini MB, Musuraca G, Lanza F, Cerchione C, Martinelli G. Gottardi M, et al. Among authors: musuraca g. Cancers (Basel). 2021 Sep 11;13(18):4566. doi: 10.3390/cancers13184566. Cancers (Basel). 2021. PMID: 34572794 Free PMC article. Review.
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma.
Arcari A, Rigacci L, Tucci A, Puccini B, Usai SV, Cavallo F, Fabbri A, Balzarotti M, Pelliccia S, Luminari S, Pennese E, Zilioli VR, Mahmoud AM, Musuraca G, Marino D, Sartori R, Botto B, Gini G, Zanni M, Hohaus S, Tarantini G, Flenghi L, Tani M, Di Rocco A, Merli M, Vallisa D, Pagani C, Nassi L, Dessì D, Ferrero S, Cencini E, Bernuzzi P, Mammi C, Marcheselli L, Tabanelli V, Spina M, Merli F. Arcari A, et al. Among authors: musuraca g. Blood Adv. 2023 Aug 8;7(15):4160-4169. doi: 10.1182/bloodadvances.2023009839. Blood Adv. 2023. PMID: 37276080 Free PMC article.
80 results